{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:50Z","timestamp":1740135170268,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["11961071"],"award-info":[{"award-number":["11961071"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"14-th Five-Year Plan Distinctive Program of Public Health and Preventive Medicine in Higher Education Institutions of Xinjiang Uygur Autonomous Region"},{"name":"Natural Science Foundation of Xinjiang","award":["2021D01C268"],"award-info":[{"award-number":["2021D01C268"]}]},{"name":"Tianjin Medical University start-up funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10250-1","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:25:08Z","timestamp":1734513908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparing the protection of heterologous booster of inhaled Ad5-nCoV vaccine and hybrid immunity against Omicron BA.5 infection: a cohort study of hospital staff in China"],"prefix":"10.1186","volume":"24","author":[{"given":"Kai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengzhi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongkang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc K.C.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naijun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianghong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"10250_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1056\/NEJMc2206576","volume":"387","author":"NP Hachmann","year":"2022","unstructured":"Hachmann NP, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387:86\u20138.","journal-title":"N Engl J Med"},{"key":"10250_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2807\/1560-7917.ES.2022.27.6.2200042","volume":"27","author":"JA Backer","year":"2022","unstructured":"Backer JA, et al. Shorter serial intervals in SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December 2021. Eurosurveillance. 2022;27:5.","journal-title":"Eurosurveillance"},{"unstructured":"WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern. (https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern, October 21, 2022).","key":"10250_CR3"},{"unstructured":"WHO. Weekly epidemiological update on COVID-19\u201319. October 2022. (https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---19-october-2022, October 19, 2022).","key":"10250_CR4"},{"key":"10250_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao Y, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593\u2013602.","journal-title":"Nature"},{"key":"10250_CR6","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon A, et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422\u2013.","journal-title":"Cell"},{"key":"10250_CR7","doi-asserted-by":"publisher","first-page":"E475","DOI":"10.1016\/S2468-2667(20)30164-X","volume":"5","author":"LH Nguyen","year":"2020","unstructured":"Nguyen LH, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5:E475\u201383.","journal-title":"Lancet Public Health"},{"doi-asserted-by":"crossref","unstructured":"Yang J et al. Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Med 19(2021).","key":"10250_CR8","DOI":"10.1186\/s12916-021-01923-8"},{"unstructured":"Coronavirus. Hong Kong will launch mass vaccination drive next week, with priority given to 2.4 million frontline workers and those in high-risk groups. (https:\/\/www.scmp.com\/news\/hong-kong\/health-environment\/article\/3122137\/coronavirus-hong-kong-approves-emergency-use)","key":"10250_CR9"},{"key":"10250_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.vaccine.2021.12.032","volume":"40","author":"E Poukka","year":"2022","unstructured":"Poukka E, et al. Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020-October 2021. Vaccine. 2022;40:701\u20135.","journal-title":"Vaccine"},{"key":"10250_CR11","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","volume":"385","author":"T Pilishvili","year":"2021","unstructured":"Pilishvili T, et al. Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel. N Engl J Med. 2021;385:e90.","journal-title":"N Engl J Med"},{"key":"10250_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(22)00007-1","volume":"399","author":"L-G Bekker","year":"2022","unstructured":"Bekker L-G, et al. Effectiveness of the Ad26.COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399:1141\u201353.","journal-title":"Lancet"},{"key":"10250_CR13","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro APS, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258\u201376.","journal-title":"Lancet"},{"key":"10250_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/jmv.27350","volume":"94","author":"AU Keskin","year":"2022","unstructured":"Keskin AU, Bolukcu S, Ciragil P, Topkaya AE. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. J Med Virol. 2022;94:39\u201341.","journal-title":"J Med Virol"},{"doi-asserted-by":"crossref","unstructured":"Ranzani OT et al., Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against Omicron in Brazil. medRxiv, 2022.2003.2030.22273193 (2022).","key":"10250_CR15","DOI":"10.1038\/s41467-022-33169-0"},{"doi-asserted-by":"crossref","unstructured":"Sapkota B et al. Heterologous prime-boost strategies for COVID-19 vaccines. J Travel Med 29(2022).","key":"10250_CR16","DOI":"10.1093\/jtm\/taab191"},{"key":"10250_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/S1473-3099(22)00746-0","volume":"22","author":"Why hybrid immunity","year":"2022","unstructured":"Why hybrid immunity. Is so triggering. Lancet Infect Dis. 2022;22:1649\u20131649.","journal-title":"Lancet Infect Dis"},{"doi-asserted-by":"crossref","unstructured":"Bobrovitz N et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis (2023).","key":"10250_CR18","DOI":"10.1016\/S1473-3099(22)00801-5"},{"key":"10250_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1126\/science.abn4947","volume":"376","author":"JRC Pulliam","year":"2022","unstructured":"Pulliam JRC, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376:596\u2013.","journal-title":"Science"},{"doi-asserted-by":"crossref","unstructured":"Tan ST et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat Med (2023).","key":"10250_CR20","DOI":"10.1101\/2022.08.08.22278547"},{"key":"10250_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41541-022-00594-7","volume":"7","author":"L Huang","year":"2022","unstructured":"Huang L, et al. Comparing hybrid and regular COVID-19 vaccine-induced immunity against the Omicron epidemic. NPJ Vaccines. 2022;7:162.","journal-title":"NPJ Vaccines"},{"doi-asserted-by":"crossref","unstructured":"Swarnalekha N et al. T resident helper cells promote humoral responses in the lung. Sci Immunol 6(2021).","key":"10250_CR22","DOI":"10.1126\/sciimmunol.abb6808"},{"key":"10250_CR23","doi-asserted-by":"publisher","first-page":"2045853","DOI":"10.1080\/21645515.2022.2045853","volume":"18","author":"K Dhama","year":"2022","unstructured":"Dhama K, et al. COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother. 2022;18:2045853.","journal-title":"Hum Vaccin Immunother"},{"key":"10250_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/22221751.2022.2030199","volume":"11","author":"F Xu","year":"2022","unstructured":"Xu F, et al. Safety, mucosal and systemic immunopotency of an aerosolized adenovirus-vectored vaccine against SARS-CoV-2 in rhesus macaques. Emerg Microbes Infect. 2022;11:438\u201341.","journal-title":"Emerg Microbes Infect"},{"doi-asserted-by":"crossref","unstructured":"Langel SN et al. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model. Sci Transl Med 14(2022).","key":"10250_CR25","DOI":"10.1126\/scitranslmed.abn6868"},{"key":"10250_CR26","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu S, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021;21:1654\u201364.","journal-title":"Lancet Infect Dis"},{"key":"10250_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2213-2600(22)00087-X","volume":"10","author":"J-X Li","year":"2022","unstructured":"Li J-X, et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial. Lancet Respiratory Med. 2022;10:739\u201348.","journal-title":"Lancet Respiratory Med"},{"key":"10250_CR28","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1080\/22221751.2022.2132881","volume":"11","author":"J Zhong","year":"2022","unstructured":"Zhong J, et al. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants. Emerg Microbes Infect. 2022;11:2689\u201397.","journal-title":"Emerg Microbes Infect"},{"doi-asserted-by":"crossref","unstructured":"Jin L et al. Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial. Emerg Microbes Infections 12(2023).","key":"10250_CR29","DOI":"10.1080\/22221751.2022.2155251"},{"key":"10250_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jobb.2022.12.002","volume":"4","author":"J Gao","year":"2022","unstructured":"Gao J. Vaccination with CanSinoBIO\u2019s inhaled COVID-19 vaccine has begun in China. J Biosaf Biosecur. 2022;4:163.","journal-title":"J Biosaf Biosecur"},{"unstructured":"Times G. Urumqi enforces \u2018static management\u2019 in parts of city to stem new wave of coronavirus resurgence. (https:\/\/www.globaltimes.cn\/page\/202208\/1272640.shtml, August 10, 2022).","key":"10250_CR31"},{"doi-asserted-by":"crossref","unstructured":"Zeng T et al. Effectiveness of the booster dose of inactivated COVID-19 vaccine against Omicron BA.5 infection: a matched cohort study of adult close contacts. Respir Res 24(2023).","key":"10250_CR32","DOI":"10.1186\/s12931-023-02542-y"},{"key":"10250_CR33","doi-asserted-by":"publisher","first-page":"e235755","DOI":"10.1001\/jamanetworkopen.2023.5755","volume":"6","author":"K Wang","year":"2023","unstructured":"Wang K, et al. Transmission characteristics and inactivated vaccine effectiveness against transmission of SARS-CoV-2 Omicron BA.5 variants in Urumqi, China. JAMA Netw Open. 2023;6:e235755.","journal-title":"JAMA Netw Open"},{"unstructured":"Agency TXN. The safety and effectiveness of COVID-19 vaccines in China -- the Joint prevention and control mechanism of The State Council answers questions on vaccination. (http:\/\/www.gov.cn\/govweb\/xinwen\/2022-07\/23\/content_5702572.htm, July 23, 2022).","key":"10250_CR34"},{"key":"10250_CR35","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"10250_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403\u201316.","journal-title":"N Engl J Med"},{"key":"10250_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99\u2013111.","journal-title":"Lancet"},{"key":"10250_CR38","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1093\/cid\/ciac488","volume":"75","author":"VL Richardson","year":"2022","unstructured":"Richardson VL, et al. Vaccine effectiveness of CanSino (Adv5-nCoV) coronavirus disease 2019 (COVID-19) vaccine among Childcare Workers-Mexico, March-December 2021. Clin Infect Dis. 2022;75:S167\u201373.","journal-title":"Clin Infect Dis"},{"doi-asserted-by":"crossref","unstructured":"Huang Z et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. BMC Med 20(2022).","key":"10250_CR39","DOI":"10.1186\/s12916-022-02606-8"},{"doi-asserted-by":"crossref","unstructured":"Chavda VP, Vora LK, Apostolopoulos V. Inhalable vaccines: can they help Control Pandemics? Vaccines (Basel) 10(2022).","key":"10250_CR40","DOI":"10.3390\/vaccines10081309"},{"doi-asserted-by":"crossref","unstructured":"King RG et al. Single-dose Intranasal Administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from Lethal Challenge. Vaccines 9(2021).","key":"10250_CR41","DOI":"10.3390\/vaccines9080881"},{"doi-asserted-by":"crossref","unstructured":"van der Ley PA, Zariri A, van Riet E, Oosterhoff D, Kruiswijk CP. An intranasal OMV-Based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection. Front Immunol 12(2021).","key":"10250_CR42","DOI":"10.3389\/fimmu.2021.781280"},{"key":"10250_CR43","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1080\/21645515.2020.1805992","volume":"16","author":"R Mudgal","year":"2020","unstructured":"Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccines Immunotherapeutics. 2020;16:2921\u201331.","journal-title":"Hum Vaccines Immunotherapeutics"},{"unstructured":"Epsi NJ et al. Understanding hybrid immunity: comparison and predictors of Humoral Immune responses to severe Acute Respiratory Syndrome Coronavirus 2 infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) vaccines. Clin Infect Dis (2022).","key":"10250_CR44"},{"key":"10250_CR45","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.cell.2022.03.018","volume":"185","author":"LB Rodda","year":"2022","unstructured":"Rodda LB, et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185:1588\u2013.","journal-title":"Cell"},{"doi-asserted-by":"crossref","unstructured":"Anderson M et al. SARS-CoV-2 antibody responses in Infection-Naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open 4(2021).","key":"10250_CR46","DOI":"10.1001\/jamanetworkopen.2021.19741"},{"doi-asserted-by":"crossref","unstructured":"Hwang J-Y et al. Humoral and Cellular Responses to COVID-19 Vaccines in SARS-CoV-2 Infection-Naive and -Recovered Korean Individuals. Vaccines 10(2022).","key":"10250_CR47","DOI":"10.3390\/vaccines10020332"},{"key":"10250_CR48","doi-asserted-by":"publisher","first-page":"eabq3511","DOI":"10.1126\/sciimmunol.abq3511","volume":"7","author":"CI Kaku","year":"2022","unstructured":"Kaku CI, et al. Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. Sci Immunol. 2022;7:eabq3511\u20133511.","journal-title":"Sci Immunol"},{"key":"10250_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jmv.29625","volume":"96","author":"G Song","year":"2024","unstructured":"Song G, Li R, Cheng MQ. Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: a systematic review and meta-analysis. J Med Virol. 2024;96:13.","journal-title":"J Med Virol"},{"key":"10250_CR50","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/S1473-3099(23)00350-X","volume":"23","author":"JX Li","year":"2023","unstructured":"Li JX, et al. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3trial. Lancet Infect Dis. 2023;23:1143\u201352.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10250-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:05:00Z","timestamp":1734516300000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10250-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10250"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10250-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee of Xinjiang Medical University. Medical records were kept confidential in full at the Sixth Affiliated Hospital of Xinjiang Medical University, and the personal identity of the subjects was not and will not be disclosed in any report on the results of this study. Informed consent is obtained from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1401"}}